Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver

Publication date: 11 January 2016
Source:Cancer Cell, Volume 29, Issue 1
Author(s): Kerry A. Rogers, John C. Byrd
Inhibitors of B cell receptor signaling substantially changed the treatment of chronic lymphocytic leukemia as the first targeted agents to enter routine clinical practice. A recent paper by Roberts and colleagues describes an additional therapeutic target by reporting encouraging clinical results with venetoclax, an inhibitor of the antiapoptotic protein BCL2.

Teaser

Inhibitors of B cell receptor signaling substantially changed the treatment of chronic lymphocytic leukemia as the first targeted agents to enter routine clinical practice. A recent paper by Roberts and colleagues describes an additional therapeutic target by reporting encouraging clinical results with venetoclax, an inhibitor of the antiapoptotic protein BCL2.


from Cancer via ola Kala on Inoreader http://ift.tt/1ZiLPBY
via IFTTT